Clinical trial
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients…
NCT00457678 · Vitreous -Retina- Macula Consultants of New York, Other · Withdrawn
Key facts
| NCT number | NCT00457678 |
|---|---|
| Title | Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself |
| Official title | A Multicenter, Randomized, Single-Masked Comparison of Lucentis™ Monotherapy With Triple Therapy of Reduced Fluence Visudyne-Lucentis-Dexamethasone (V-L-D) in Patients With CNV Secondary to AMD as Second Line Therapy After Lucentis Monotherapy |
| Lead sponsor | Vitreous -Retina- Macula Consultants of New York, Other |
| Collaborators | QLT Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Age Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | Visudyne, Lucentis, Dexamethasone |
| Enrollment | 0 |
| Start date | Jan 1, 2007 |
| Primary completion | Dec 4, 2007 |
| Completion | Dec 4, 2007 |
| First posted | Apr 6, 2007 |
| Last update posted | Aug 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: